These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38611052)

  • 61. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.
    Alafandi A; van Garderen KA; Klein S; van der Voort SR; Rizopoulos D; Nabors L; Stupp R; Weller M; Gorlia T; Tonn JC; Smits M
    Eur J Cancer; 2023 Jul; 188():122-130. PubMed ID: 37235895
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
    Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
    Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
    Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
    J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
    Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
    J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
    Dahlrot RH; Larsen P; Boldt HB; Kreutzfeldt MS; Hansen S; Hjelmborg JB; Kristensen BW
    J Neuropathol Exp Neurol; 2019 Jul; 78(7):633-640. PubMed ID: 31058280
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study.
    Caccese M; Simonelli M; Villani V; Rizzato S; Ius T; Pasqualetti F; Russo M; Rudà R; Amoroso R; Bellu L; Bertorelle R; Cavallin F; Dipasquale A; Carosi M; Pizzolitto S; Cesselli D; Persico P; Casini B; Fassan M; Zagonel V; Lombardi G
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626029
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
    J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study.
    Chen J; Wang T; Liu W; Qiu H; Zhang N; Chen X; Ding X; Zhang L
    Front Oncol; 2022; 12():1000501. PubMed ID: 36483042
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative analysis of
    Gibson D; Ravi A; Rodriguez E; Chang S; Oberheim Bush N; Taylor J; Clarke J; Solomon D; Scheffler A; Witte J; Lambing H; Okada H; Berger M; Chehab F; Butowski NA
    Neurooncol Adv; 2023; 5(1):vdad115. PubMed ID: 37899778
    [TBL] [Abstract][Full Text] [Related]  

  • 74. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
    Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
    Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Szylberg M; Sokal P; Śledzińska P; Bebyn M; Krajewski S; Szylberg Ł; Szylberg A; Szylberg T; Krystkiewicz K; Birski M; Harat M; Włodarski R; Furtak J
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009577
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series.
    Bertolini F; Zunarelli E; Baraldi C; Valentini A; Del Giovane C; Depenni R; Falasca A; Giacobazzi P; Malagoli M; Meletti S; Fontana A; Conte P;
    Tumori; 2012 Nov; 98(6):756-61. PubMed ID: 23389363
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 80. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.